CERCA
MCID: CRV047
MIFTS: 65

Cervical Cancer, Somatic (CERCA) malady

Categories: Genetic diseases (common), Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervical Cancer, Somatic

About this section

Aliases & Descriptions for Cervical Cancer, Somatic:

Name: Cervical Cancer, Somatic 52 12
Cervical Cancer 35 11 70 50 38 2 13 68
Uterine Cervical Neoplasm 11 68
Cervix Cancer 11 70
Uterine Cervical Neoplasms 39
Neoplasm of Uterine Cervix 11
Tumor of the Cervix Uteri 11
 
Malignant Tumor of Cervix 68
Uterine Cervical Cancer 70
Cervix Uteri Cancer 11
Cervical Carcinoma 50
Cervical Neoplasm 11
Cervix Carcinoma 68
Cerca 70

Classifications:



External Ids:

OMIM52 603956
Disease Ontology11 DOID:4362
ICD1030 C53, C53.9
ICD9CM32 180, 180.9
MeSH39 D002583
NCIt45 C2940, C9311
MedGen37 C0302592

Summaries for Cervical Cancer, Somatic

About this section
MedlinePlus:38 The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. cervical cancer is caused by a virus called hpv. the virus spreads through sexual contact. most women's bodies are able to fight hpv infection. but sometimes the virus leads to cancer. you're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have hiv infection. cervical cancer may not cause any symptoms at first. later, you may have pelvic pain or bleeding from the vagina. it usually takes several years for normal cells in the cervix to turn into cancer cells. your health care provider can find abnormal cells by doing a pap test to examine cells from the cervix. you may also have an hpv test. if your results are abnormal, you may need a biopsy or other tests. by getting regular screenings, you can find and treat any problems before they turn into cancer. treatment may include surgery, radiation therapy, chemotherapy, or a combination. the choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. vaccines can protect against several types of hpv, including some that can cause cancer. nih: national cancer institute

MalaCards based summary: Cervical Cancer, Somatic, also known as cervical cancer, is related to proctitis and testicular cancer, and has symptoms including pelvic pain, neoplasm and abnormality of the cervical spine. An important gene associated with Cervical Cancer, Somatic is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways are LncRNA-mediated mechanisms of therapeutic resistance and Transcriptional activation of cell cycle inhibitor p21. Affiliated tissues include the cervix, uterus and cervix, and related mouse phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor).

Disease Ontology:11 A female reproductive organ cancer that is located in the cervix.

CDC:2 Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later.

UniProtKB/Swiss-Prot:70 Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

Description from OMIM:52 603956

Related Diseases for Cervical Cancer, Somatic

About this section

Diseases related to Cervical Cancer, Somatic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 206)
idRelated DiseaseScoreTop Affiliating Genes
1proctitis29.4CASP3, CDKN1A, CDKN2A, MMP2, MYC, TP53
2testicular cancer29.3BIRC5, CDKN1A, CDKN2A, FGFR3, MMP2, RB1
3cervix carcinoma11.5
4cervical intraepithelial neoplasia11.3
5cervicitis11.1
6carcinosarcoma of the cervix uteri11.1
7radiation proctitis11.1
8cervical adenosquamous carcinoma10.8
9cervix disease10.7
1013q12.3 microdeletion syndrome10.4CDKN1A, CDKN2A, FGFR3
11clear cell adenofibroma10.3CDKN2A, TP53
12uterine cervix leukoplakia10.3CDKN2A, FHIT, TP53
13lacrimal gland adenoid cystic carcinoma10.3CDKN2A, TP53
14cryoglobulinemia10.3CDKN2A, FGFR3, FHIT, TP53
15ampulla of vater neoplasm10.3CCNB1, CDKN2A, TP53
16cervical verrucous carcinoma10.3CDKN1A, CDKN2A, RB1, TP53
17prinzmetal's variant angina10.3BIRC5, CASP3, MYC
18fallopian tube adenocarcinoma10.3CASP3, CDKN1A, CDKN2A, TP53
19statin toxicity10.3BIRC5, FHIT, TP53
20prostate cancer, hereditary, x-linked 110.3BAX, CDKN1A, FGFR3, TP53
21fallopian tube leiomyosarcoma10.3CDKN2A, DAPK1, TP53
22subglottis neoplasm10.3CDKN1A, CDKN2A, MMP2
23breast leiomyoma10.3CDKN2A, FGFR3, MMP2, TP53
24nasopharyngeal carcinoma10.3BAX, CDKN1A, CDKN2A, TP53
25postmenopausal atrophic vaginitis10.3CASP3, CASP8, MYC, TP53
26chondrodysplasia punctata, rhizomelic, type 310.3CASP3, TP53
27connective tissue benign neoplasm10.3CASP3, CDKN2A, TP53
28mitochondrial encephalomyopathy10.3CDKN2A, MMP2, TP53
29cystadenoma10.3CASP3, CASP8, MYC, TP53
30papillary transitional carcinoma10.3CASP3, FGFR3, FHIT, RB1, TP53
31traumatic brain injury10.3CASP3, CDKN2A, MMP2, TP53
32inverted follicular keratosis10.3BIRC5, CDKN1A, PARP1, TP53
33charcot-marie-tooth disease type 2n10.3BIRC5, CDKN2A, TERT
34marginal zone b-cell lymphoma10.3CASP8, CDKN2A, MMP2, TP53
35extraocular retinoblastoma10.3CDKN1A, CDKN2A, MYC, RB1, TP53
36melanoma metastasis10.3CASP3, CDKN2A, MYC, TP53
37integumentary system benign neoplasm10.3CDKN1A, CDKN2A, MYC, RB1, TP53
38juvenile astrocytoma10.3FGFR3, MMP2, RB1, TP53
39ornithinemia10.3CASP3, CDKN2A, MMP2, TP53
40post-surgical hypoinsulinemia10.3CDKN1A, CDKN2A, MYC, RB1, TP53
41glucose-6-phosphate translocase deficiency10.2CDKN1A, CDKN2A, MYC, RB1, TP53
42adult astrocytic tumour10.2CDKN1A, CDKN2A, MYC, RB1, TP53
43monoclonal paraproteinemia10.2BAX, CASP3, CASP8, CDKN1A
44childhood-onset cerebral x-linked adrenoleukodystrophy10.2CDKN2A, DAPK1, TP53
45bladder disease10.2BAX, CASP3, CDKN2A, MYC, TP53
46lower lip cancer10.2BIRC5, CASP3, CASP8, MMP2
47lattice corneal dystrophy10.2CASP3, CDKN1A, CDKN2A, MMP2, TP53
48autonomic nervous system neoplasm10.2CDKN1A, CDKN2A, FGFR3, RB1, TP53, UBE3A
49in situ pulmonary adenocarcinoma10.2CASP3, CDKN1A, CDKN2A, MMP2, TP53
50maxillary sinus cholesteatoma10.2CDKN1A, CDKN2A, MMP2, TERT, TP53

Comorbidity relations with Cervical Cancer, Somatic via Phenotypic Disease Network (PDN):


Deficiency AnemiaHydronephrosis
Vaginal CancerAcute Cystitis
Intestinal Obstruction

Graphical network of the top 20 diseases related to Cervical Cancer, Somatic:



Diseases related to cervical cancer, somatic

Symptoms & Phenotypes for Cervical Cancer, Somatic

About this section


Clinical features from OMIM:

603956

Human phenotypes related to Cervical Cancer, Somatic:

 64
id Description HPO Frequency HPO Source Accession
1 neoplasm64 HP:0002664
2 abnormality of the cervical spine64 HP:0003319

UMLS symptoms related to Cervical Cancer, Somatic:


pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00250-A-39.9BAX, CASP8, CCNB1, CDKN1A, PARP1, TP53
2GR00250-A-17.2BAX, BIRC5, CASP3, CASP8, CASP9, CDKN1A

MGI Mouse Phenotypes related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

41 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000118610.2CASP3, CDKN2A, MYC, RB1, TP53
2MP:00053829.8CASP3, CASP9, CDKN1A, FGFR3, MMP2, MYC
3MP:00053779.6BAX, CASP3, CDKN1A, FGFR3, MYC, PARP1
4MP:00053919.6BAX, CASP3, CDKN1A, CDKN2A, FGFR3, MMP2
5MP:00053809.4BIRC5, CASP8, CASP9, CDKN1A, CDKN2A, MYC
6MP:00053679.3BAX, CASP3, CASP8, CDKN1A, DAPK1, FGFR3
7MP:00020069.2BAX, CASP8, CDKN1A, CDKN2A, FGFR3, FHIT
8MP:00053699.2BAX, CASP3, CASP8, CDKN1A, CDKN2A, MMP2
9MP:00053909.2BAX, CASP3, CDKN1A, CDKN2A, FGFR3, MMP2
10MP:00030129.1CASP3, CDKN1A, CDKN2A, FGFR3, MYC, PARP1
11MP:00053819.0CA9, CASP3, CDKN1A, CDKN2A, FGFR3, FHIT
12MP:00053898.9BAX, CADM1, CASP3, CDKN1A, CDKN2A, FGFR3
13MP:00053868.8BAX, CADM1, CASP3, CDKN1A, CDKN2A, DAPK1
14MP:00053888.8BAX, CASP3, CASP8, CASP9, CDKN1A, CDKN2A
15MP:00107718.8CASP3, CASP8, CDKN1A, CDKN2A, FGFR3, FHIT
16MP:00053768.1BAX, BIRC5, CASP3, CASP8, CDKN1A, CDKN2A
17MP:00053788.1BAX, CADM1, CASP3, CASP8, CASP9, CDKN1A
18MP:00053798.1BAX, BIRC5, CA9, CADM1, CASP3, CASP8
19MP:00053848.0BAX, BIRC5, CADM1, CASP3, CASP8, CASP9
20MP:00107687.8BAX, BIRC5, CA9, CASP3, CASP8, CASP9
21MP:00053877.7BAX, BIRC5, CA9, CADM1, CASP3, CASP8
22MP:00036317.4BAX, CADM1, CASP3, CASP8, CASP9, CDKN1A
23MP:00053977.4BAX, BIRC5, CA9, CADM1, CASP3, CASP8

Drugs & Therapeutics for Cervical Cancer, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Avastin16 44 BEVACIZUMAB Genentech July 2009
FDA Label: Avastin
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:16 Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:14 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:16 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
2
Cervarix16 44 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
FDA Label: -
Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18
Indications and Usage:16 -
DrugBank Targets: -
Mechanism of Action:16 
Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins
Action: activates/ provokes production
FDA: -
3
Gardasil16 44 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
FDA Label: Gardasil
Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus
Indications and Usage:16 GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7)
DrugBank Targets: -
Mechanism of Action:16 
Target: humoral immune response
Action: inducer
FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Cervical Cancer, Somatic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 475)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
2
MeperidineapprovedPhase 47557-42-14058
Synonyms:
1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester
1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]
1-Methyl-4-phenylisonipecotic acid, ethyl ester
1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester
4-Carbethoxy-1-methyl-4-phenylpiperidine
4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester
50-13-5 (hydrochloride)
57-42-1
610593_ALDRICH
610593_FLUKA
AC1L1HBJ
C07128
CHEBI:122528
CHEMBL607
CID4058
D008614
D08343
DB00454
DEA No. 9230
Demarol
Demerol
DivK1c_000983
Dolcontral
Dolosal
Dolsin
EINECS 200-329-1
Ethyl 1-methyl-4-phenylisonipecotate
Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate
HSDB 3116
IDI1_000983
Isonipecain
Isonipecaine
Isonipecaïne
Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester
KBio1_000983
 
L000908
LS-85121
Lidol
Lydol
Meperidine
Meperidine solution
Meperidol
Methyl phenylpiperidine carbonic acid ethyl ester
MolPort-001-785-564
N-Methyl-4-phenyl-4-carbethoxypiperidine
NINDS_000983
Nemerol
Operidine EPJ I
Operidine EPJ-I
Pethanol
Pethidin
Pethidine
Pethidine (INN)
Pethidine DBL
Pethidine DBL (TN)
Pethidine dbl
Pethidineter
Pethidinum
Pethidinum [INN-Latin]
Petidina
Petidina [INN-Spanish]
Petydyna
Petydyna [Polish]
Phetidine
Piperosal
Pipersal
Péthidine
Sauteralgyl
Spasmedal
Spasmodolin
UNII-9E338QE28F
YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)
meperidine
3
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 3821437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
4
Aluminum hydroxideapprovedPhase 4, Phase 3, Phase 221021645-51-2
Synonyms:
Al(OH)3
Aluminium hydroxide
Aluminium hydroxide gel, dried
 
Aluminium hydroxide, dried
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
5
Diazepamapproved, illicit, vet_approvedPhase 4126439-14-53016
Synonyms:
1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
11100-37-1
439-14-5
5-24-04-00300 (Beilstein Handbook Reference)
53320-84-6
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepine
7-Chloro-1-methyl-5-3H-1,4-benzodiazepin-2(1H)-one
7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-Chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one
7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
A3662/0155188
AC-10561
AC1L1EZE
AKOS003367969
Alboral
Aliseum
Alupram
Amiprol
An-Ding
Ansilive
Ansiolin
Ansiolisina
Antenex
Anxicalm
Anxionil
Apaurin
Apo-Diazepam
Apo-diazepam
Apozepam
Armonil
Arzepam
Assival
Atensine
Atilen
Azedipamin
BIDD:GT0105
BIDD:PXR0158
BRD-K16508793-001-01-8
BRN 0754371
BSPBio_003279
Baogin
Bensedin
Benzopin
Best [Pharaceutical]
Betapam
Bialzepam
Britazepam
C06948
CB 4261
CCRIS 6009
CHEBI:49575
CHEMBL12
CID3016
CPD000058398
Calmaven
Calmocitene
Calmociteno
Calmod
Calmpose
Caudel
Centrazepam
Cercine
Ceregulart
Chuansuan
Condition
D-Pam
D00293
D003975
D0899_SIGMA
D9900_FLUKA
D9900_SIGMA
DAP
DB00829
DB07699
DEA No. 2765
DZP
Desconet
Desloneg
Diacepan
Diaceplex
Dialag
Dialar
Diapam
Diapax
Diapine
Diaquel
Diastat
Diastat (TN)
Diastat Acudial
Diatran
Diazapam
Diazem
Diazemuls
Diazemulus
Diazepam
Diazepam (JP15/USP/INN)
Diazepam Dak
Diazepam Desitin
Diazepam Elmu
Diazepam Fabra
Diazepam Intensol
Diazepam Nordic
Diazepam Rectubes
Diazepam Stada
Diazepam [USAN:INN:BAN:JAN]
Diazepam solution
Diazepam-Eurogenerics
Diazepam-Lipuro
Diazepam-ratiopharm
Diazepamu
Diazepamu [Polish]
Diazepamum
Diazepamum [INN-Latin]
Diazepan
Diazepan leo
Diazepin
Diazetard
Dienpax
Dipam
Dipaz
Dipezona
Disopam
DivK1c_000967
Dizac
Domalium
Doval
Drenian
Ducene
Duksen
Dupin
Duxen
E-Pam
EINECS 207-122-5
Elcion CR
Eridan
Euphorin P
Eurosan
Evacalm
Faustal
Faustan
Faustan,
Freudal
Frustan
Gewacalm
Gihitan
Gradual
Gubex
HMS2051N04
HMS503A15
HSDB 3057
I06-0194
IDI1_000967
Iazepam
 
Jinpanfan
KBio1_000967
KBio3_002780
KBioGR_001012
Kabivitrum
Kiatrium
Kratium
Kratium 2
LA 111
LA III
LA-111
LS-122
La-Iii
Lamra
Lembrol
Levium
Liberetas
Lizan
Lovium
MLS000759402
Mandro
Mandro-Zep
Mandrozep
Medipam
Mentalium
Metamidol
Methyl diazepinone
Methyldiazepinone
Methyldiazepinone (pharmaceutical)
Methyldiazepinone, pharmaceutical
Metil Gobanal
MolPort-001-729-114
Morosan
NCGC00178168-01
NINDS_000967
NSC 169897
NSC-77518
NSC169897
NSC77518
Nellium
Nerozen
Nervium
Neurolytril
Nivalen
Nixtensyn
Noan
Notense
Novazam
Novo-Dipam
Novodipam
Oprea1_126223
Ortopsique
Paceum
Pacitran
Paralium
Paranten
Parzam
Paxate
Paxel
Paxum
Placidox 10
Placidox 2
Placidox 5
Plidan
Pms-Diazepam
Pomin
Pro-Pam
ProPAM
Prozepam
Psychopax
Q-Pam
Q-Pam Relanium
Q-pam
Quetinil
Quiatril
Quievita
Radizepam
Relaminal
Relanium
Reliver
Renborin
Ro 5-2805
Ro 5-2807
Ruhsitus
S.A. R.L
S.a. r.l.
SAM001246536
SMR000058398
STK735517
Saromet
Sedapam
Sedipam
Seduksen
Seduxen
Serenack
Serenamin
Serenzin
Servizepam
Setonil
Sibazon
Sibazone
Sico Relax
Simasedan
Sipam
Solis
Sonacon
Spectrum3_001780
Spectrum4_000576
Spectrum5_001890
Stesolid
Stesolin
T-quil
Tensium
Tensopam
Tranimul
Trankinon
Tranqdyn
Tranquase
Tranquirit
Tranquo-Puren
Tranquo-Tablinen
Tranquo-puren
Tranquo-tablinen
Trazepam
UNII-Q3JTX2Q7TU
Umbrium
Unisedil
Usempax Ap
Usempax ap
Valaxona
Valeo
Valiquid
Valitran
Valium
Valium (TN)
Valium R
Valrelease
Valuzepam
Vanconin
Vatran
Vazen
Vazepam
Velium
Vival
Vivol
WLN: T67 GNV JN IHJ CG G1 KR
WY-3467
Winii
Wy 3467
ZINC00006427
Zepaxid
Zetran
Zipan
diazepam
e-Pam
nchembio.307-comp2
nchembio747-comp27
neurolytr il
6
NicotineapprovedPhase 4, Phase 1, Phase 2110354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
7
Dexamethasoneapproved, investigational, vet_approvedPhase 4, Phase 3217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
8
IronapprovedPhase 4, Phase 1, Phase 211657439-89-623925
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
ATW 230
ATW 432
Ancor B
Ancor en 80/150
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
C00023
C3518_SIAL
C3518_SIGMA
CCRIS 1580
CHEBI:18248
CID23925
Carbonyl iron
Copy Powder CS 105-175
D007501
DB01592
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Diseases (animal), iron overload
Diseases, iron overload
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
 
Ed-In-Sol
Eisen
Electrolytic iron
F 60 (metal)
FE
FT 3 (element)
Fe
Fe-40
Fe1+
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrousal
Ferrovac E
Ferrum
Ferrum metallicum
GS 6
HF 2 (element)
HL (iron)
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Hemocyte
Hierro
Hoeganaes ATW 230
Hoeganaes EH
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
LOHA
LS-3196
MolPort-003-925-001
NC 100
PZh-1M3
PZh-2
PZh1M1
PZh2M
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
Reduced iron
Remko
SUY-B 2
Siderol
UNII-E1UOL152H7
Vitedyn-Slo
Yieronia
fer
ferrous iron
hierro
9DienogestapprovedPhase 4, Phase 24265928-58-7
10
BethanecholapprovedPhase 44674-38-42370
Synonyms:
(2-Hydroxypropyl)trimethylammonium carbamate
1-Propanaminium, 2-((aminocarbonyl)oxy)-N,N,N-trimethyl- (9CI)
2-((Aminocarbonyl)oxy)-N,N,N-trimethyl-1-propanaminium
2-(Carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
2-Carbamoyloxypropyl-trimethylazanium
2-carbamoyloxypropyl(trimethyl)azanium
2-carbamoyloxypropyl-trimethylazanium
590-63-6 (chloride)
674-38-4
AB00053794
AC1L1DJ2
Amidopropyldimethylbetaine
Ammonium, (2-hydroxypropyl)trimethyl-, carbamate (ester)
BPBio1_001196
BRN 1773706
BSPBio_001086
BSPBio_001902
BTC
Besacholine
Bethaine Choline Chloride
Bethanechol
Bethanechol Chloride
Bethanecol
C06850
C7H17N2O2
CHEBI:3084
CHEMBL1482
CID2370
Carbamoyl-beta-methylcholine
Carbamyl-beta-methylcholine
Carbamylmethylcholine Chloride
DB01019
 
DivK1c_000179
HMS2089I08
IDI1_000179
KBio1_000179
KBio2_000504
KBio2_003072
KBio2_005640
KBio3_001402
KBioGR_000690
KBioSS_000504
LS-18498
Lopac0_000304
Myotonine chloride
NCGC00015245-06
NCGC00089770-02
NCGC00163217-01
NINDS_000179
Prestwick0_001073
Prestwick1_001073
Prestwick2_001073
Prestwick3_001073
SPBio_000204
SPBio_002993
Spectrum2_000132
Spectrum3_000311
Spectrum4_000255
Spectrum5_000892
Spectrum_000084
UNII-004F72P8F4
Urabeth
beta-Methyl Carbachol Chloride
bethanechol
carbamoyl-β-methylcholine
carbamyl-β-methylcholine
11
Nandrolone decanoateapproved, illicitPhase 433360-70-39677
Synonyms:
19-nortestosterone decanoate
 
Nandrolone 17β-decanoate
Norandrostenolone decanoate
Nortestosterone decanoate
12
Nandroloneapproved, illicit, experimentalPhase 433434-22-0, 62-90-89904, 229455
Synonyms:
(17-beta)-17-Hydroxyestr-4-en-3-one
(17beta)-17-hydroxyestr-4-en-3-one
(8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-Estr-4-Ene-3-One
17-beta-Hydroestr-4-en-3-one
17-hydroxyestr-4-en-3-one
17beta-Hydroxy-19-nor-4-androsten-3-one
17beta-Hydroxy-19-norandrost-4-en-3-one
17beta-Hydroxy-4-estren-3-one
17beta-hydroxyestr-4-en-3-one
19-Norandrostenolone
19-Nortestosterone
19-nortestosterone
19NTPP
4-Estren-17beta-ol-3-one
434-22-0
46476_FLUKA
46476_RIEDEL
74640_ALDRICH
74640_FLUKA
AC-15207
AC1L1U32
C07254
C18H26O2
CHEBI:7466
CHEMBL757
CID9904
CPD000058610
D08250
Deca-Durabolin
Durabolin
EINECS 207-101-0
Estr-4-en-3-one, 17-hydroxy-, (17-beta)- (9CI)
Estr-4-en-3-one, 17-hydroxy-, (17beta)- (9CI)
Estr-4-en-3-one, 17beta-hydroxy- (8CI)
Estrenolone
HMS2051I04
HSDB 3368
LMST02010044
LS-64851
LT03330030
 
MLS002222325
Menidrabol
MolPort-003-849-312
N7252_SIGMA
NCGC00159416-02
NPP
NSC 3351
NTPP
Nadrolone
Nadrolone phenylpropionate
Nandrolin
Nandrolon
Nandrolon phenylpropionate
Nandrolona
Nandrolona [INN-Spanish]
Nandrolone (INN)
Nandrolone Base
Nandrolone Decanoate
Nandrolone Decanoic acid
Nandrolone Phenpropionate
Nandrolone cIII
Nandrolone phenylpionate
Nandrolone phenylpropionate
Nandrolonum
Nandrolonum [INN-Latin]
Norandrolone phenyl propionate
Norandrostenolon
Norandrostenolone
Norandrostenolone phenylpropionate
Nortestonate
Nortestosterone
Nortestosterone phenylpropionate
Nortestosteronum
Oestrenolon
SAM001246751
SMR000058610
Testosterone phenylpropionate
U 2410
UNII-6PG9VR430D
ZINC03814379
decadura
decadura (TN)
nandrolone
13
Vitamin Capproved, nutraceuticalPhase 4, Phase 253150-81-75785, 54670067
Synonyms:
(+)-Sodium L-ascorbate
(+)-ascorbate
(+)-ascorbic acid
(2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one
(2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one
(5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one
129940-97-2
134-03-2 (monosodium salt)
14536-17-5
154170-90-8
2-(1,2-Dihydroxyethyl)-4,5-dihydroxyfuran-3-one
255564_SIAL
259133-78-3
3-Keto-L-gulofuranolactone
3-Oxo-L-gulofuranolactone
3-Oxo-L-gulofuranolactone (enol form)
30208-61-8
33034_RIEDEL
33034_SIAL
47863_SUPELCO
47A605F0-4187-47A8-B0CE-F9E7DA1B0076
50-81-7
50976-75-5
56172-55-5
56533-05-2
57304-74-2
57606-40-3
623158-95-2
6730-29-6
882690-91-7
884381-69-5
885512-24-3
88845-26-5
89924-69-6
95209_FLUKA
95209_SIGMA
95210_FLUKA
95210_SIAL
95212_FLUKA
A0278_SIGMA
A0537
A2174_SIGMA
A2218_SIGMA
A2343_SIGMA
A4403_SIGMA
A4544_SIGMA
A5960_SIGMA
A7506_SIGMA
A92902_ALDRICH
A92902_SIAL
AB00376923
AB1002440
AC1L1L4T
AC1Q77S6
AR-1J3435
Acid Ascorbic
Acide ascorbique
Acide ascorbique [INN-French]
Acido ascorbico
Acido ascorbico [INN-Spanish]
Acidum ascorbicum
Acidum ascorbicum [INN-Latin]
Acidum ascorbinicum
Adenex
Allercorb
Ambap36431-82-0
Antiscorbic vitamin
Antiscorbutic factor
Antiscorbutic vitamin
Arco-cee
Ascoltin
Ascoltin (TN)
Ascor-B.I.D.
Ascorb
Ascorbajen
Ascorbate
Ascorbic Acid
Ascorbic Acid, Monosodium Salt
Ascorbic acid
Ascorbic acid (JP15/USP/INN)
Ascorbic acid [BAN:INN:JAN]
Ascorbic acid [INN:BAN:JAN]
Ascorbicab
Ascorbicap
Ascorbicap (TN)
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorbyl radical
Ascorin
Ascorteal
Ascorvit
BPBio1_000363
BSPBio_000329
C-Level
C-Long
C-Quin
C-Span
C-Vimin
C00072
C6H8O6
CCRIS 57
CE-VI-Sol
CHEBI:29073
CHEMBL196
CID5785
Cantan
Cantaxin
Caswell No. 061B
Catavin C
Ce lent
Ce-Mi-Lin
Ce-mi-lin
Ce-vi-sol
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-Caps TD
Cee-Vite
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-Caps TC
Cetane-Caps TD
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
 
Cevatine
Cevex
Cevi-Bid
Cevi-bid
Cevimin
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
Ciamin
Cipca
Citriscorb
Citrovit
Colascor
Concemin
Cortalex
D00018
DB00126
Davitamon C
Dora-C-500
Duoscorb
EINECS 200-066-2
FEMA No. 2109
Ferancee
Ferrous ascorbate
HSDB 818
HiCee
Hicee
Hybrin
IDO-C
Ido-C
Iron(II) ascorbate
Iron-ascorbic acid complexes
Juvamine
Kangbingfeng
Kyselina askorbova
Kyselina askorbova [Czech]
L(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbate
L-(+)-Ascorbic Acid
L-(+)-Ascorbic acid
L-(+)-ascorbic acid
L-3-Ketothreohexuronic acid lactone
L-3-ketothreohexuronic acid
L-Ascorbate
L-Ascorbic Acid
L-Ascorbic acid
L-Ascorbic acid, free radical form
L-Lyxoascorbate
L-Lyxoascorbic acid
L-Threo-ascorbic acid
L-Threoascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
L-ascorbate
L-threo-Hex-2-enonic acid, gamma-lactone
L-threo-ascorbic acid
L-threo-hex-2-enono-1,4-lactone
LS-145
Laroscorbine
Lemascorb
Liqui-Cee
Liqui-cee
MLS002153776
Magnesium Ascorbicum
Magnorbin
Meri-C
Meri-c
MolPort-001-792-501
Monodehydroascorbic acid
NCGC00091517-01
NCGC00091517-02
NCGC00164357-01
NCI-C54808
NSC 33832
Natrascorb
Natrascorb injectable
Oral Vitamin C
Planavit C
Prestwick3_000325
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
SMR001233160
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Sodascorbate
Sodium Ascorbate (Ascorbic Acid)
Stuartinic
Suncoat VC 40
Sunkist
Testascorbic
Tolfrinic
UNII-PQ6CK8PD0R
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100M
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamin- C
Vitamin-?C
Vitamisin
Vitascorbol
W210901_ALDRICH
Xitix
acide ascorbique
acidum ascorbicum
acidum ascorbinicum
antiscorbic vita min
ascor-b.i.d
ascorbate
ascorbic acid
bmse000182
cee-caps td
cevibid
component of Cortalex
component of E and C-Level
component of Endoglobin Forte
component of Ferancee
gamma-Lactone L-threo-Hex-2-enonate
gamma-Lactone L-threo-Hex-2-enonic acid
l-ascorbic acid
l-threo-hex-1-eofuranos-3-ulose
nchembio.174-comp5
nchembio.89-comp1
nchembio.92-comp2
nchembio821-comp9
roscorbi c
vitamin C
ácido ascórbico
14Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113180
15HormonesPhase 4, Phase 3, Phase 2, Phase 114415
16Epoetin alfaPhase 4, Phase 3658113427-24-0
17EstrogensPhase 4, Phase 3, Phase 2, Phase 12542
18AnestheticsPhase 4, Phase 3, Phase 2, Early Phase 19596
19Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 113168
20
protease inhibitorsPhase 4, Phase 3, Phase 2, Phase 15471
Synonyms:
 
protease inhibitors
21Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18402
22Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
23Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 15592
24HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 15470
25Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 118340
26HematinicsPhase 4, Phase 3, Phase 2, Phase 11684
27AntibodiesPhase 4, Phase 3, Phase 2, Phase 16394
28Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
29Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113403
30VaccinesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 16611
31ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16394
32glucocorticoidsPhase 4, Phase 3, Phase 1, Phase 25103
33Contraceptive AgentsPhase 4, Phase 21967
34Trace ElementsPhase 4, Phase 3, Phase 1, Phase 26001
35AndrogensPhase 4, Phase 11321
36Anabolic AgentsPhase 4, Phase 1513
37Contraceptive Agents, MalePhase 4, Phase 2233
38Dexamethasone acetatePhase 4, Phase 321711177-87-3
39MicronutrientsPhase 4, Phase 3, Phase 1, Phase 26001
40VitaminsPhase 4, Phase 3, Phase 1, Phase 25282
41Contraceptives, OralPhase 4, Phase 21327
42NarcoticsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 13646
43Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 123689
44DisinfectantsPhase 4582
45Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 18192
46Anesthetics, IntravenousPhase 4, Phase 32538
47Anesthetics, GeneralPhase 4, Phase 32934
48Dexamethasone 21-phosphatePhase 4, Phase 32171
49Adjuvants, AnesthesiaPhase 4, Phase 31674
50AnalgesicsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 111733

Interventional clinical trials:

(show top 50)    (show all 1230)
idNameStatusNCT IDPhase
1Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in ChinaUnknown statusNCT01021904Phase 4
2Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?Unknown statusNCT01101750Phase 4
3The Self-Collection Study: a Study of Self-collected HPV Testing and Results CounselingUnknown statusNCT01843478Phase 4
4Can Alternative Treatment Have an Impact on Cervical Dysplasia?Unknown statusNCT00842738Phase 4
5Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune DiseaseUnknown statusNCT00815282Phase 4
6Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical CancerCompletedNCT01988376Phase 4
7Epoetin Beta in Treating Anemia in Patients With Cervical CancerCompletedNCT00046969Phase 4
8Effect of HPV Vaccination on Women Aged 25 YearsCompletedNCT02296255Phase 4
9Patient Navigation in the Safety Net:CONNECTeDDCompletedNCT00613275Phase 4
10Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian GirlsCompletedNCT01173900Phase 4
11Alternate Dosing Schedules Study for HPV Vaccine (ADS)CompletedNCT02280642Phase 4
12Alternate Dosing Schedules Study for HPV VaccineCompletedNCT00862810Phase 4
13V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)CompletedNCT01544478Phase 4
14Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female SubjectsCompletedNCT00947115Phase 4
15Reactogenicity Study of Cervarix and Gardasil in UK Adolescent GirlsCompletedNCT00956553Phase 4
16Comparison of Meperidine and Fentanyl on Pain Scale and QOL in BrachytherapyCompletedNCT02684942Phase 4
17Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy AdolescentsCompletedNCT00534638Phase 4
18Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) InfectionCompletedNCT01571141Phase 4
19Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
20Management of Cervical Intraepithelial Neoplasia Grade 2CompletedNCT00733109Phase 4
21Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel DiseaseCompletedNCT01034358Phase 4
22The Effect of Nutritional Counseling for Cancer PatientsCompletedNCT01962272Phase 4
23Effect of Hormone Replacement Therapy on Lupus ActivityCompletedNCT00392093Phase 4
24Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone TreatmentCompletedNCT01372904Phase 4
25Comparing Health Services Interventions for the Prevention of HPV-related CancerRecruitingNCT02837926Phase 4
26Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.RecruitingNCT01953107Phase 4
27Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) StudyRecruitingNCT01824537Phase 4
28CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study)Active, not recruitingNCT01895517Phase 4
29The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)Active, not recruitingNCT02629510Phase 4
30FASTER-Tlalpan StudyActive, not recruitingNCT03105856Phase 4
31Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in IndiaActive, not recruitingNCT00923702Phase 4
32Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected FemalesActive, not recruitingNCT01031069Phase 4
33Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsActive, not recruitingNCT02624349Phase 4
34Ohio Patient Navigator Research ProgramActive, not recruitingNCT01569672Phase 4
35Effectiveness of Cervical Screening in HPV Vaccinated WomenEnrolling by invitationNCT02149030Phase 4
36Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV VaccinesNot yet recruitingNCT03180034Phase 4
37Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIANot yet recruitingNCT02910596Phase 4
38HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal LesionsNot yet recruitingNCT03051516Phase 4
39Endometrial Preparation Before Operative Hysteroscopy in Premenopausal WomenNot yet recruitingNCT02440750Phase 4
40Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved CommunitiesTerminatedNCT00629993Phase 4
41Evaluate Safety of a Vaccine Against Cervical Cancer (HPV-16/18 L1/AS04) in Healthy Filipino Females Aged 10 Yrs & AboveTerminatedNCT00730847Phase 4
42Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good PrognosisUnknown statusNCT00846508Phase 3
43Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical CancerUnknown statusNCT00548821Phase 3
44Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical CancerUnknown statusNCT00842660Phase 3
45Usefulness of FDG-PET for Advanced Cervical CancerUnknown statusNCT00146458Phase 3
46Hydralazine Valproate for Cervical CancerUnknown statusNCT00532818Phase 3
47Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical CarcinomaUnknown statusNCT01405235Phase 3
48The IMAP Study Improving Management of Mildly Abnormal Pap SmearsUnknown statusNCT00119509Phase 3
49Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)Unknown statusNCT01095198Phase 2, Phase 3
50Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer PatientsUnknown statusNCT00122746Phase 3

Search NIH Clinical Center for Cervical Cancer, Somatic


Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer, Somatic

About this section

Anatomical Context for Cervical Cancer, Somatic

About this section

MalaCards organs/tissues related to Cervical Cancer, Somatic:

36
Uterus, Cervix, Testes, Endothelial, T cells, Breast, Lung

FMA organs/tissues related to Cervical Cancer, Somatic:

17
The cervix

Publications for Cervical Cancer, Somatic

About this section

Variations for Cervical Cancer, Somatic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer, Somatic:

70
id Symbol AA change Variation ID SNP ID
1FGFR3p.Ser249CysVAR_004149rs121913483

Clinvar genetic disease variations for Cervical Cancer, Somatic:

5 (show all 29)
id Gene Variation Type Significance SNP ID Assembly Location
1HRASNM_ 005343.3(HRAS): c.34G> A (p.Gly12Ser)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
2HRASNM_ 005343.3(HRAS): c.35G> C (p.Gly12Ala)SNVPathogenic/ Likely pathogenicrs104894230GRCh37Chr 11, 534288: 534288
3HRASNM_ 005343.3(HRAS): c.37G> T (p.Gly13Cys)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
4HRASNM_ 005343.3(HRAS): c.436G> A (p.Ala146Thr)SNVPathogenic/ Likely pathogenicrs104894231GRCh37Chr 11, 533467: 533467
5HRASNM_ 005343.3(HRAS): c.437C> T (p.Ala146Val)SNVPathogenic/ Likely pathogenicrs121917759GRCh37Chr 11, 533466: 533466
6HRASNM_ 005343.3(HRAS): c.34G> T (p.Gly12Cys)SNVPathogenic/ Likely pathogenicrs104894229GRCh37Chr 11, 534289: 534289
7PIK3CANM_ 006218.3(PIK3CA): c.3140A> G (p.His1047Arg)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
8PIK3CANM_ 006218.3(PIK3CA): c.3140A> T (p.His1047Leu)SNVPathogenic/ Likely pathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
9PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
10PIK3CANM_ 006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)SNVPathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
11AKT1NM_ 005163.2(AKT1): c.49G> A (p.Glu17Lys)SNVPathogenic/ Likely pathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
12PIK3CANM_ 006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)SNV, HaplotypePathogenic/ Likely pathogenicrs121913274GRCh37Chr 3, 178936092: 178936092
13FGFR3NM_ 000142.4(FGFR3): c.746C> G (p.Ser249Cys)SNVPathogenic/ Likely pathogenicrs121913483GRCh37Chr 4, 1803568: 1803568
14CTNNB1NM_ 001904.3(CTNNB1): c.110C> G (p.Ser37Cys)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
15CTNNB1NM_ 001904.3(CTNNB1): c.110C> T (p.Ser37Phe)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
16HRASNM_ 005343.3(HRAS): c.38G> T (p.Gly13Val)SNVPathogenic/ Likely pathogenicrs104894226GRCh38Chr 11, 534285: 534285
17PIK3CANM_ 006218.3(PIK3CA): c.1635G> T (p.Glu545Asp)SNVPathogenic/ Likely pathogenicrs121913275GRCh37Chr 3, 178936093: 178936093
18SMAD4NM_ 005359.5(SMAD4): c.1081C> G (p.Arg361Gly)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918
19SMAD4NM_ 005359.5(SMAD4): c.1082G> A (p.Arg361His)SNVPathogenic/ Likely pathogenicrs377767347GRCh37Chr 18, 48591919: 48591919
20PIK3CANM_ 006218.3(PIK3CA): c.1624G> A (p.Glu542Lys)SNVPathogenic/ Likely pathogenicrs121913273GRCh37Chr 3, 178936082: 178936082
21HRASNM_ 005343.3(HRAS): c.37G> C (p.Gly13Arg)SNVPathogenic/ Likely pathogenicrs104894228GRCh37Chr 11, 534286: 534286
22CTNNB1NM_ 001904.3(CTNNB1): c.110C> A (p.Ser37Tyr)SNVPathogenic/ Likely pathogenicrs121913403GRCh37Chr 3, 41266113: 41266113
23PIK3CANM_ 006218.3(PIK3CA): c.1633G> C (p.Glu545Gln)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
24ERBB2NM_ 004448.3(ERBB2): c.2305G> C (p.Asp769His)SNVPathogenic/ Likely pathogenicrs121913468GRCh38Chr 17, 39724008: 39724008
25ERBB2NM_ 001005862.2(ERBB2): c.2215G> T (p.Asp739Tyr)SNVPathogenic/ Likely pathogenicrs121913468GRCh37Chr 17, 37880261: 37880261
26TP53NM_ 000546.5(TP53): c.713G> T (p.Cys238Phe)SNVPathogenic/ Likely pathogenicrs730882005GRCh37Chr 17, 7577568: 7577568
27PIK3CANM_ 006218.3(PIK3CA): c.3139C> T (p.His1047Tyr)SNVPathogenic/ Likely pathogenicrs121913281GRCh37Chr 3, 178952084: 178952084
28PTENNM_ 000314.6(PTEN): c.389G> A (p.Arg130Gln)SNVPathogenic/ Likely pathogenicrs121909229GRCh37Chr 10, 89692905: 89692905
29SMAD4NM_ 005359.5(SMAD4): c.1081C> T (p.Arg361Cys)SNVPathogenic/ Likely pathogenicrs80338963GRCh37Chr 18, 48591918: 48591918

Copy number variations for Cervical Cancer, Somatic from CNVD:

6 (show top 50)    (show all 142)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137471127800000GainEPHB2Cervical cancer
2164251124300000247249719ArmCervical cancer
3303101241700000247249719GainCervical cancer
431746130500000163800000GainAIM2Cervical cancer
53217513440000039600000GainCDCA8Cervical cancer
647124108960000098000000LossPTENCervical cancer
74864511101600000102400000AmplificationMMP1Cervical cancer
84864611101600000102400000AmplificationMMP13Cervical cancer
95176111130300000134452384LossCervical cancer
105179111130800000135006516LossHNTCervical cancer
115179211130800000135006516LossOPCMLCervical cancer
12554351152900000134452384LossCervical cancer
13570951163100000130300000LossINT2Cervical cancer
14570961163100000130300000LossMEN1Cervical cancer
155709769938930099393387LossPOUF3Cervical cancer
16570981163100000130300000LossTRIM29Cervical cancer
1759362117470000085300000GainCervical cancer
1877051133950000052200000LossRBCervical cancer
198104414100400000106368585GainAKT1Cervical cancer
209728016140700000LossCervical cancer
2110674117111200000LossTP53Cervical cancer
22108734172220000028800000LossCCL2Cervical cancer
23109725172850000029700000AmplificationCervical cancer
24109738172880000035400000AmplificationERBB2Cervical cancer
25111034173490000035300000AmplificationCervical cancer
26111283173540000054900000AmplificationABCC3Cervical cancer
27112092173785625337884915AmplificationERBB2Cervical cancer
28112304173854477238574202AmplificationTOP2ACervical cancer
29117589177290000078774742GainCervical cancer
3012410319130200000GainCervical cancer
3112410419130200000LossCervical cancer
321241771916900000GainSMARCA4Cervical cancer
331242191916900000GainCervical cancer
341245971911567971179434DeletionLKB1Cervical Cancer
351245981911567971179434DeletionLKB1Cervical cancer
36130163194780000057600000GainLIG1Cervical cancer
3713416519950000014500000GainCervical cancer
381403882197100000242951149LossCASP10Cervical cancer
391403892197100000242951149LossCFLARCervical cancer
401403902197100000242951149LossPPP1R7Cervical cancer
41151917202710000028400000AmplificationAHCYCervical cancer
42151918202710000028400000AmplificationASXL1Cervical cancer
43151919202710000028400000AmplificationC20orf20Cervical cancer
44151920202710000028400000AmplificationE2F1Cervical cancer
45151921202710000028400000AmplificationGSSCervical cancer
46151922202710000028400000AmplificationKIF3BCervical cancer
47151923202710000028400000AmplificationPOFUT1Cervical cancer
48151924202710000028400000AmplificationTPX2Cervical cancer
49153446203710000041100000GainAIB1Cervical cancer
50153736204110000049200000AmplificationADNPCervical cancer

Expression for genes affiliated with Cervical Cancer, Somatic

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cervical Cancer, Somatic patients vs. healthy controls: 35 (show all 70)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1KRT1keratin 1, type IIUterus-5.470.000
2KRTDAPkeratinocyte differentiation-associated proteinUterus-4.960.000
3CTHRC1collagen triple helix repeat containing 1Uterus+4.650.000
4TMPRSS11Btransmembrane protease, serine 11BUterus-4.580.000
5CDKN2Acyclin-dependent kinase inhibitor 2AUterus+4.450.000
6CMPK2cytidine monophosphate (UMP-CMP) kinase 2, mitochondrialUterus+4.320.000
7CRNNcornulinUterus-4.250.000
8MALmal, T-cell differentiation proteinUterus-4.210.000
9DSG1desmoglein 1Uterus-4.170.000
10ECT2epithelial cell transforming 2Uterus+4.100.000
11SYCP2synaptonemal complex protein 2Uterus+3.950.000
12HS6ST2heparan sulfate 6-O-sulfotransferase 2Uterus+3.940.000
13KIF14kinesin family member 14Uterus+3.880.000
14IFI44interferon-induced protein 44Uterus+3.880.000
15MMP1matrix metallopeptidase 1Uterus+3.830.001
16GREB1growth regulation by estrogen in breast cancer 1Uterus-3.780.000
17KRT17keratin 17, type IUterus+3.710.000
18SPINK7serine peptidase inhibitor, Kazal type 7 (putative)Uterus-3.700.000
19NUF2NUF2, NDC80 kinetochore complex componentUterus+3.700.000
20NCEH1neutral cholesterol ester hydrolase 1Uterus+3.640.000
21PLSCR1phospholipid scramblase 1Uterus+3.630.000
22E2F7E2F transcription factor 7Uterus+3.620.000
23SLF1SMC5-SMC6 complex localization factor 1Uterus+3.610.000
24INHBAinhibin, beta AUterus+3.590.001
25DAPL1death associated protein-like 1Uterus-3.570.000
26KRT4keratin 4, type IIUterus-3.530.000
27SMC4structural maintenance of chromosomes 4Uterus+3.500.000
28CEP55centrosomal protein 55kDaUterus+3.490.000
29LOXlysyl oxidaseUterus+3.480.000
30ANLNanillin actin binding proteinUterus+3.480.000
31ITGB1integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)Uterus+3.460.000
32CRISP3cysteine-rich secretory protein 3Uterus-3.460.001
33HELLShelicase, lymphoid-specificUterus+3.440.000
34KRT19keratin 19, type IUterus+3.440.002
35SPP1secreted phosphoprotein 1Uterus+3.430.000
36CNFNcornifelinUterus-3.420.000
37EPCAMepithelial cell adhesion moleculeUterus+3.390.000
38NDC80NDC80 kinetochore complex componentUterus+3.350.000
39SCDstearoyl-CoA desaturase (delta-9-desaturase)Uterus+3.310.000
40CRCT1cysteine-rich C-terminal 1Uterus-3.310.002
41KRT13keratin 13, type IUterus-3.300.010
42CDK1cyclin-dependent kinase 1Uterus+3.300.000
43DDIT4DNA-damage-inducible transcript 4Uterus+3.290.000
44ARMT1acidic residue methyltransferase 1Uterus+3.290.000
45ALOX12arachidonate 12-lipoxygenaseUterus-3.280.000
46ATAD2ATPase family, AAA domain containing 2Uterus+3.270.000
47ZIC2Zic family member 2Uterus+3.260.000
48ARHGAP21Rho GTPase activating protein 21Uterus+3.240.000
49LYNLYN proto-oncogene, Src family tyrosine kinaseUterus+3.240.000
50PPIBpeptidylprolyl isomerase B (cyclophilin B)Uterus+3.230.000
51CSTF3cleavage stimulation factor, 3' pre-RNA, subunit 3, 77kDaUterus+3.200.000
52TFRCtransferrin receptorUterus+3.190.000
53TOP2Atopoisomerase (DNA) II alphaUterus+3.180.000
54S100A8S100 calcium binding protein A8Uterus-3.180.000
55ASPMabnormal spindle microtubule assemblyUterus+3.160.000
56B4GALT4UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4Uterus+3.150.000
57EDN3endothelin 3Uterus-3.150.000
58CXCL8chemokine (C-X-C motif) ligand 8Uterus+3.140.000
59RAD51AP1RAD51 associated protein 1Uterus+3.120.000
60HNRNPH2heterogeneous nuclear ribonucleoprotein H2 (H')Uterus+3.120.000
61DTLdenticleless E3 ubiquitin protein ligase homolog (Drosophila)Uterus+3.120.000
62NASPnuclear autoantigenic sperm protein (histone-binding)Uterus+3.090.000
63ESRGembryonic stem cell related (non-protein coding)Uterus-3.070.000
64CENPKcentromere protein KUterus+3.060.000
65PLATplasminogen activator, tissueUterus+3.040.000
66SPINK5serine peptidase inhibitor, Kazal type 5Uterus-3.030.000
67TMEFF2transmembrane protein with EGF-like and two follistatin-like domains 2Uterus-3.020.000
68EREGepiregulinUterus-3.020.000
69ISG15ISG15 ubiquitin-like modifierUterus+3.010.001
70KNTC1kinetochore associated 1Uterus+3.010.000

Search GEO for disease gene expression data for Cervical Cancer, Somatic.

Pathways for genes affiliated with Cervical Cancer, Somatic

About this section

Pathways related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

(show top 50)    (show all 102)
idSuper pathwaysScoreTop Affiliating Genes
110.2CDKN1A, TP53
2
Show member pathways
10.2CDKN1A, TP53
310.1CASP8, PARP1
410.1FGFR3, MYC, TP53
510.0CDKN1A, MYC, TP53
610.0CDKN1A, MYC, TP53
710.0CDKN1A, RB1, UBE3A
810.0CDKN1A, MYC, RB1
910.0CDKN1A, MYC, RB1
1010.0BAX, CDKN1A, TP53
1110.0BAX, CDKN1A, TP53
1210.0MYC, TERT, UBE3A
1310.0CCNB1, CDKN1A, TP53
14
Show member pathways
10.0CCNB1, CDKN1A, TP53
15
Show member pathways
10.0CASP3, CASP9, TP53
1610.0BAX, BIRC5, TP53
1710.0BAX, CASP8, MYC
1810.0CCNB1, CDKN1A, MYC
199.9BAX, CASP3, TERT
209.9CASP3, CASP8, CASP9
219.9CASP3, CASP8, CASP9
22
Show member pathways
9.9BAX, CASP3, CASP9
23
Show member pathways
9.9BAX, CASP8, CASP9
249.9CDKN1A, CDKN2A, RB1, TP53
259.9BAX, CASP3, MMP2
269.9MMP2, MYC, TERT
279.9CDKN2A, MYC, RB1, TP53
289.9CDKN1A, MYC, RB1, TP53
29
Show member pathways
9.9CDKN1A, CDKN2A, MYC, RB1
309.9CASP3, MYC, RB1, TP53
31
Show member pathways
9.9CA9, FGFR3, MMP2
32
Show member pathways
9.9CDKN1A, MYC, TERT, TP53
339.8BAX, CASP9, CDKN1A, TP53
34
Show member pathways
9.8BAX, CCNB1, CDKN1A, TP53
35
Show member pathways
9.8BAX, CASP3, CASP9, TP53
36
Show member pathways
9.8CASP3, CASP8, CASP9, CDKN1A
37
Show member pathways
9.8CASP3, CASP8, CASP9, DAPK1
389.8CDKN1A, CDKN2A, MYC, RB1, TP53
39
Show member pathways
9.8BAX, CASP3, CASP8, CASP9
40
Show member pathways
9.8BAX, CASP3, CASP8, CASP9
419.8BAX, CASP3, CASP8, CASP9
42
Show member pathways
9.7BIRC5, CASP3, CASP8, CASP9
43
Show member pathways
9.7BAX, CDKN1A, CDKN2A, MYC, TP53
449.7BAX, CDKN1A, CDKN2A, MYC, TP53
459.7CASP3, CASP8, CASP9, MMP2
469.7CASP9, CDKN1A, FGFR3, MYC, TP53
479.7CASP9, FHIT, MYC, RB1, TP53
48
Show member pathways
9.7CASP3, CASP8, CASP9, PARP1
499.7CA9, CASP3, CASP9, CDKN1A
509.7CCNB1, CDKN1A, CDKN2A, RB1, TP53

GO Terms for genes affiliated with Cervical Cancer, Somatic

About this section

Cellular components related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1death-inducing signaling complexGO:003126411.0CASP3, CASP8
2nucleolusGO:000573010.1CA9, CDKN1A, CDKN2A, MYC, PARP1, TERT
3mitochondrionGO:00057399.7BAX, CASP8, CASP9, CDKN2A, FHIT, MMP2
4protein complexGO:00432349.6CASP8, CDKN1A, MYC, PARP1, TP53
5nucleoplasmGO:00056549.4BIRC5, CASP3, CASP8, CCNB1, CDKN1A, CDKN2A
6cytoplasmGO:00057378.7BAX, BIRC5, CASP3, CASP8, CASP9, CCNB1
7nucleusGO:00056348.2BAX, BIRC5, CA9, CASP3, CASP9, CCNB1

Biological processes related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 43)
idNameGO IDScoreTop Affiliating Genes
1activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayGO:009729610.9BAX, CASP8
2signal transduction by p53 class mediatorGO:007233110.8CDKN1A, TP53
3intrinsic apoptotic signaling pathway by p53 class mediatorGO:007233210.8BAX, FHIT, TP53
4intrinsic apoptotic signaling pathwayGO:009719310.8BAX, CDKN1A, TP53
5negative regulation of cyclin-dependent protein serine/threonine kinase activityGO:004573610.8CASP3, CDKN1A, CDKN2A
6negative regulation of fibroblast proliferationGO:004814710.8BAX, MYC, TP53
7ovarian follicle developmentGO:000154110.7BAX, MYC, UBE3A
8glial cell apoptotic processGO:003434910.7CASP3, CASP9, RB1
9neuron apoptotic processGO:005140210.7BAX, CASP3, RB1
10activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome cGO:000863510.7BAX, CASP3, CASP9
11execution phase of apoptosisGO:009719410.7CASP3, CASP8, CASP9
12extrinsic apoptotic signaling pathway in absence of ligandGO:009719210.7BAX, CASP3, CASP9
13positive regulation of fibroblast proliferationGO:004814610.7CCNB1, CDKN1A, MYC
14response to X-rayGO:001016510.7CASP3, CDKN1A, TP53
15G1/S transition of mitotic cell cycleGO:000008210.7CDKN1A, CDKN2A, MYC, RB1
16response to cobalt ionGO:003202510.6CASP3, CASP8, CASP9
17Ras protein signal transductionGO:000726510.6CDKN1A, CDKN2A, RB1, TP53
18response to woundingGO:000961110.6BAX, CASP3, MYC
19response to UVGO:000941110.6CASP3, CASP9, CDKN1A
20apoptotic signaling pathwayGO:009719010.6BAX, CASP3, CASP8, DAPK1
21cellular response to UVGO:003464410.6BAX, CASP9, MYC, TP53
22replicative senescenceGO:009039910.6CDKN1A, CDKN2A, TERT, TP53
23DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.6BAX, CCNB1, CDKN1A, TP53
24cellular response to hypoxiaGO:007145610.6CCNB1, MYC, TERT, TP53
25cell cycle arrestGO:000705010.5CDKN1A, CDKN2A, MYC, RB1, TP53
26regulation of mitotic cell cycleGO:000734610.5BIRC5, CDKN1A, MYC, RB1
27positive regulation of neuron apoptotic processGO:004352510.5BAX, CASP3, CASP9, TP53
28response to antibioticGO:004667710.5CASP3, CASP8, CASP9, TP53
29regulation of cell cycleGO:005172610.5BAX, CCNB1, CDKN1A, RB1
30negative regulation of cell proliferationGO:000828510.5BAX, CDKN1A, CDKN2A, RB1, TP53
31response to estradiolGO:003235510.5CASP3, CASP8, CASP9, MYC
32response to gamma radiationGO:001033210.4BAX, MYC, PARP1, TP53
33activation of cysteine-type endopeptidase activity involved in apoptotic processGO:000691910.4BAX, CASP3, CASP8, CASP9, CDKN2A
34positive regulation of apoptotic processGO:004306510.4BAX, CASP3, CASP9, CDKN2A, TP53
35negative regulation of gene expressionGO:001062910.4CCNB1, CDKN1A, MYC, RB1, TERT
36cellular response to organic cyclic compoundGO:007140710.3CASP3, CASP8, CASP9, CCNB1, MYC
37cell cycleGO:000704910.3BIRC5, CCNB1, CDKN1A, CDKN2A, RB1, TP53
38response to drugGO:004249310.2CA9, CASP3, CCNB1, CDKN1A, MYC
39regulation of apoptotic processGO:004298110.1BAX, BIRC5, CASP8, CASP9, DAPK1, TP53
40negative regulation of apoptotic processGO:004306610.1BIRC5, CASP3, CDKN1A, DAPK1, MYC, TERT
41cellular response to DNA damage stimulusGO:000697410.0BAX, CASP3, CASP9, CDKN1A, MYC, PARP1
42viral processGO:00160329.7BAX, CASP8, RB1, TP53, UBE3A
43apoptotic processGO:00069159.3BAX, BIRC5, CADM1, CASP3, CASP8, CASP9

Molecular functions related to Cervical Cancer, Somatic according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1cysteine-type endopeptidase activity involved in apoptotic processGO:009715311.0CASP3, CASP8
2cyclin-dependent protein serine/threonine kinase inhibitor activityGO:000486110.9CASP3, CDKN1A, CDKN2A
3cysteine-type endopeptidase activityGO:000419710.8CASP3, CASP8, CASP9
4cysteine-type endopeptidase activity involved in execution phase of apoptosisGO:009720010.8CASP3, CASP8, CASP9
5chaperone bindingGO:005108710.6BAX, BIRC5, TERT, TP53
6protein complex bindingGO:003240310.5CASP3, CASP8, CDKN1A, MYC
7transcription factor bindingGO:000813410.3CDKN2A, MYC, PARP1, RB1, TP53
8protein kinase bindingGO:001990110.1CASP9, CCNB1, CDKN1A, CDKN2A, PARP1, TP53
9identical protein bindingGO:004280210.0BAX, BIRC5, CASP8, DAPK1, FHIT, PARP1
10ubiquitin protein ligase bindingGO:00316259.7CASP8, CDKN1A, FHIT, RB1, TP53
11protein bindingGO:00055157.9BAX, BIRC5, CADM1, CASP3, CASP8, CASP9

Sources for Cervical Cancer, Somatic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet